Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
IVAX Research LLC |
---|---|
Information provided by: | IVAX Research LLC |
ClinicalTrials.gov Identifier: | NCT00577655 |
The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: Albuterol-HFA-MDI and placebo Drug: Albuterol-HFA-MDI |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase 3 Study to Evaluate the Chronic-Dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics |
Enrollment: | 104 |
Study Start Date: | August 2007 |
Study Completion Date: | July 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Albuterol-HFA-MDI
|
Drug: Albuterol-HFA-MDI
Albuterol-HFA-MDI 180 mcg
|
2: Placebo Comparator
Placebo-HFA-MDI
|
Drug: Albuterol-HFA-MDI and placebo
Placebo-HFA-MDI (albuterol, 0 mcg) Albuterol-HFA-MDI (albuterol, 180 mcg)
|
Eligible patients will be randomized to receive one of the following two treatments four times a day for 21 days:
Placebo-HFA-MDI (Albuterol 0 mcg) Albuterol-HFA-MDI (Albuterol 180 mcg)
Ages Eligible for Study: | 4 Years to 11 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Center for Clinical Trials of Sacramento | |
Sacramento, California, United States, 95823 | |
Center for Clinical Trials, LLC | |
Paramount, California, United States, 90723 | |
Integrated Research Group, Inc | |
Riverside, California, United States, 92506 | |
Pediatric Care Medical Group, Inc. | |
Huntington Beach, California, United States, 92647 | |
California Allergy & Asthma Medical Group | |
Palmdale, California, United States, 93551 | |
United States, Florida | |
Carlos Piniella, MD | |
Miami, Florida, United States, 33157 | |
United States, Illinois | |
Sneeze, Wheeze & Itch Associates, Inc. | |
Normal, Illinois, United States, 61761 | |
United States, New York | |
St. Elizabeth's Children Health Center | |
Utica, New York, United States, 13502 | |
Asthma & Allergy Associates, PC | |
Elmira, New York, United States, 14901 | |
ENT & Allergy Associates | |
Newburgh, New York, United States, 12550 | |
United States, North Carolina | |
Regional Allergy & Asthma Consultants | |
Asheville, North Carolina, United States, 28801 | |
United States, Oregon | |
Clinical Research Institute of Southern Oregan, PC | |
Medford, Oregon, United States, 97504 | |
United States, Virginia | |
Virginia Adult & Pediatric Allergy & Asthma | |
Richmond, Virginia, United States, 23229 |
Study Director: | Teva Study Physician MD | Teva R&D Initiative |
Responsible Party: | Ivax Research, LLC ( Ivax Research, LLC ) |
Study ID Numbers: | IXR-302-25-105 |
Study First Received: | December 18, 2007 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00577655 |
Health Authority: | United States: Food and Drug Administration |
Pediatric, asthma, albuterol-HFA and Placebo |
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Albuterol Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity |
Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Bronchial Diseases Immune System Diseases Adrenergic beta-Agonists Physiological Effects of Drugs Anti-Asthmatic Agents |
Reproductive Control Agents Adrenergic Agonists Pharmacologic Actions Tocolytic Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |